{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:59:17Z","timestamp":1778903957857,"version":"3.51.4"},"reference-count":22,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Protocols"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer drug resistance, whether intrinsic or acquired, underlies most relapses and treatment failures. Reliable preclinical models are crucial to define resistance mechanisms and test counterstrategies. This overview article concisely compares three model classes: (1) clinical, patient\u2011derived xenografts that retain tumor heterogeneity and can mirror patient resistance; (2) induced\u2011resistance models produced by prolonged drug selection in vivo or in vitro that recapitulate tumor evolution under therapy; and (3) engineered isogenic cell lines that isolate specific resistance drivers. We summarize some key resistance mechanisms revealed and potential therapeutic approaches informed by these models, including rational combinations, mutation\u2011targeted inhibitors\/degraders, efflux\/epigenetic modulators, and immune\u2010related combinations. Each model has trade\u2011offs, but integrating them accelerates mechanistic insight and translational drug development. This overview guides selection of preclinical models and design of strategies to overcome cancer drug resistance. \u00a9 2025 Wiley Periodicals LLC.<\/jats:p>","DOI":"10.1002\/cpz1.70282","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T14:24:16Z","timestamp":1765376656000},"source":"Crossref","is-referenced-by-count":1,"title":["Overview of Preclinical Drug\u2010Resistant Tumor Models and Their Application in Drug Discovery"],"prefix":"10.1002","volume":"5","author":[{"given":"Bin","family":"Li","sequence":"first","affiliation":[{"name":"In Vivo Pharmacology Unit, WuXi Biology WuXi AppTec Co., Ltd  Suzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Ni","sequence":"additional","affiliation":[{"name":"In Vivo Pharmacology Unit, WuXi Biology WuXi AppTec Co., Ltd  Suzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4180-3649","authenticated-orcid":false,"given":"Dong","family":"Wang","sequence":"additional","affiliation":[{"name":"In Vivo Pharmacology Unit, WuXi Biology WuXi AppTec Co., Ltd  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaoxiang","family":"Liu","sequence":"additional","affiliation":[{"name":"In Vivo Pharmacology Unit, WuXi Biology WuXi AppTec Co., Ltd  Suzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Shi","sequence":"additional","affiliation":[{"name":"In Vivo Pharmacology Unit, WuXi Biology WuXi AppTec Co., Ltd  Suzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2349-2437","authenticated-orcid":false,"given":"Zhixiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"In Vivo Pharmacology Unit, WuXi Biology WuXi AppTec Co., Ltd  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyang","family":"Gu","sequence":"additional","affiliation":[{"name":"In Vivo Pharmacology Unit, WuXi Biology WuXi AppTec Co., Ltd  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9629-010X","authenticated-orcid":false,"given":"Jian","family":"Xiang","sequence":"additional","affiliation":[{"name":"In Vivo Pharmacology Unit, WuXi Biology WuXi AppTec Co., Ltd  Suzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967\u2010022\u201003405\u20108"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.10990"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010019\u20101694\u20101"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010020\u201078646\u2010y"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102317"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201012\u20100049"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010020\u201017127\u20102"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.015"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.AM2024\u20105871"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201022\u20103901"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13148"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00040"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010025\u201056981\u2010w"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.AM2024\u20101946"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.06.077"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215449"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102023\u2010SITC2023.1162"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010023\u201001341\u20107"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2019.10"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058\u2010015\u20100523\u20101"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201016\u20102703"}],"container-title":["Current Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/currentprotocols.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpz1.70282","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/currentprotocols.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpz1.70282","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/currentprotocols.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpz1.70282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T22:14:05Z","timestamp":1769724845000},"score":1,"resource":{"primary":{"URL":"https:\/\/currentprotocols.onlinelibrary.wiley.com\/doi\/10.1002\/cpz1.70282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/cpz1.70282"],"URL":"https:\/\/doi.org\/10.1002\/cpz1.70282","archive":["Portico"],"relation":{},"ISSN":["2691-1299","2691-1299"],"issn-type":[{"value":"2691-1299","type":"print"},{"value":"2691-1299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"article-number":"e70282"}}